Kenneth L. Gayron - 29 Sep 2023 Form 4 Insider Report for KIORA PHARMACEUTICALS INC (KPRX)

Reporting relationship: Director
Issuer ticker: KPRX
Reported as of: 29 Sep 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Oct 2023, 16:44:02 UTC
Prior SEC filing: 19 Sep 2023
Next SEC filing: 07 Nov 2023
Source filing: View source filing
Reporting owner signature: /s/ Melissa Tosca, Attorney-in-Fact

Key filing fact

Kenneth L. Gayron filed Form 4 for KIORA PHARMACEUTICALS INC (KPRX) on 03 Oct 2023.

Key facts

This page summarizes Kenneth L. Gayron's Form 4 filing for KIORA PHARMACEUTICALS INC (KPRX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 03 Oct 2023, 16:44.

Change

Previous filing in this sequence was filed on 19 Sep 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KPRX transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +5,000
Change %
Price: $0.000000
Shares after: 5,000
Date: 29 Sep 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 5,000
Exercise price: $0.5677
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become fully exercisable on September 29, 2024.